Inhibition of B-Raf/MEK/ERK signaling suppresses DR5 expression and impairs response of cancer cells to DR5-mediated apoptosis and T cell-induced killing

Skin Cancer Associated With the Use of Sorafenib and Sunitinib for Renal Cell Carcinoma

(2013) Kathryn Breaker et al.   DERMATOLOGIC SURGERY

MEK and the inhibitors: from bench to bedside

(2013) Akintunde Akinleye et al.   Journal of Hematology & Oncology

B-Raf and the inhibitors: from bench to bedside

(2013) Tiangui Huang et al.   Journal of Hematology & Oncology

RAF Inhibition Overcomes Resistance to TRAIL-Induced Apoptosis in Melanoma Cells

(2013) Anja Berger et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Targeted therapy for melanoma: is double hitting a home run?

(2012) Keiran S. M. Smalley et al.   Nature Reviews Clinical Oncology

RAF around the Edges — The Paradox of BRAF Inhibitors

(2012) Ashani T. Weeraratna   NEW ENGLAND JOURNAL OF MEDICINE

Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

(2012) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

RASMutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors

(2012) Fei Su et al.   NEW ENGLAND JOURNAL OF MEDICINE

Retinoic Acid Enhances TRAIL-Induced Apoptosis in Cancer Cells by Upregulating TRAIL Receptor 1 Expression

(2011) L. Dhandapani et al.   CANCER RESEARCH

The novel Raf inhibitor Raf265 decreases Bcl-2 levels and confers TRAIL-sensitivity to neuroendocrine tumour cells

(2011) K. Zitzmann et al.   ENDOCRINE-RELATED CANCER

Oncogenic Ras and B-Raf Proteins Positively Regulate Death Receptor 5 Expression through Co-activation of ERK and JNK Signaling

(2011) You-Take Oh et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

A MCP1 fusokine with CCR2-specific tumoricidal activity

(2011) Moutih Rafei et al.   Molecular Cancer

The First-in-Human Study of the Hydrogen Sulfate (Hyd-Sulfate) Capsule of the MEK1/2 Inhibitor AZD6244 (ARRY-142886): A Phase I Open-Label Multicenter Trial in Patients with Advanced Cancer

(2010) U. Banerji et al.   CLINICAL CANCER RESEARCH

Proapoptotic DR4 and DR5 signaling in cancer cells: toward clinical translation

(2010) Annie Yang et al.   CURRENT OPINION IN CELL BIOLOGY

The multikinase inhibitor Sorafenib induces apoptosis and sensitises endometrial cancer cells to TRAIL by different mechanisms

(2010) D. Llobet et al.   EUROPEAN JOURNAL OF CANCER

ERK/Ribosomal S6 Kinase (RSK) Signaling Positively Regulates Death Receptor 5 Expression through Co-activation of CHOP and Elk1

(2010) You-Take Oh et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

(2010) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Treatment combinations targeting apoptosis to improve immunotherapy of melanoma

(2009) Peter Hersey et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Cutaneous Squamous Cell Carcinoma and Inflammation of Actinic Keratoses Associated with Sorafenib

(2009) Zita Dubauskas et al.   Clinical Genitourinary Cancer

Following TRAIL’s path in the immune system

(2009) Christina Falschlehner et al.   IMMUNOLOGY

Keratoacanthomas and Squamous Cell Carcinomas in Patients Receiving Sorafenib

(2009) Jean Philippe Arnault et al.   JOURNAL OF CLINICAL ONCOLOGY

Advances in Targeting the Ras/Raf/MEK/Erk Mitogen-Activated Protein Kinase Cascade with MEK Inhibitors for Cancer Therapy

(2008) B. B. Friday et al.   CLINICAL CANCER RESEARCH

Deoxyribonucleic Acid Profiling Analysis of 40 Human Thyroid Cancer Cell Lines Reveals Cross-Contamination Resulting in Cell Line Redundancy and Misidentification

(2008) Rebecca E. Schweppe et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral, Small-Molecule Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor AZD6244 (ARRY-142886) in Patients With Advanced Cancers

(2008) Alex A. Adjei et al.   JOURNAL OF CLINICAL ONCOLOGY